Terms: = Kidney tumors AND ITK, PSCTK2, 3702, Q08881, ENSG00000113263, EMT, MGC126258, LYK, MGC126257 AND Clinical Outcome
4 results:
1. Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition.
Sciacovelli M; Gonçalves E; Johnson TI; Zecchini VR; da Costa AS; Gaude E; Drubbel AV; Theobald SJ; Abbo SR; Tran MG; Rajeeve V; Cardaci S; Foster S; Yun H; Cutillas P; Warren A; Gnanapragasam V; Gottlieb E; Franze K; Huntly B; Maher ER; Maxwell PH; Saez-Rodriguez J; Frezza C
Nature; 2016 Aug; 537(7621):544-547. PubMed ID: 27580029
[TBL] [Abstract] [Full Text] [Related]
2. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.
Zhou L; Liu XD; Sun M; Zhang X; German P; Bai S; Ding Z; Tannir N; Wood CG; Matin SF; Karam JA; Tamboli P; Sircar K; Rao P; Rankin EB; Laird DA; Hoang AG; Walker CL; Giaccia AJ; Jonasch E
Oncogene; 2016 May; 35(21):2687-97. PubMed ID: 26364599
[TBL] [Abstract] [Full Text] [Related]
3. The use of automated quantitative analysis to evaluate epithelial-to-mesenchymal transition associated proteins in clear cell renal cell carcinoma.
O'Mahony FC; Faratian D; Varley J; Nanda J; Theodoulou M; Riddick AC; Harrison DJ; Stewart GD
PLoS One; 2012; 7(2):e31557. PubMed ID: 22363672
[TBL] [Abstract] [Full Text] [Related]
4. Human renal cancer cells express a novel membrane-bound interleukin-15 that induces, in response to the soluble interleukin-15 receptor alpha chain, epithelial-to-mesenchymal transition.
Khawam K; Giron-Michel J; Gu Y; Perier A; Giuliani M; Caignard A; Devocelle A; Ferrini S; Fabbi M; Charpentier B; Ludwig A; Chouaib S; Azzarone B; Eid P
Cancer Res; 2009 Feb; 69(4):1561-9. PubMed ID: 19190330
[TBL] [Abstract] [Full Text] [Related]
